Evidence dossier · candidate cand-covid-pericarditis · CICP program · · DRAFT — not a determination
This is a draft research-tracking dossier, not a determination that COVID-19 vaccine causes Pericarditis, and not an incidence or legal finding. All evidence is flagged needs_human_review and must be reviewed before any page is published or cited. Every value is grounded in retrieved citations (PMID + retrieval date); unsourced items read "no evidence found / not assessable". Symmetric search: every supporting query has a mirror/null query, and zeros are shown (negative dossiers report the absence of signal).
Claim matrix (C1–C6, computed)
Claim
Label
Status
Missing nodes
C1
Coherent clinical object exists
supported
C2
Consistent temporal window
supported
C3
Epidemiologic excess risk
contested
C4
Consistency / replication
contested
C5
Specificity (product / dose)
contested
C6
Biological mechanism
contested
Two evidentiary bars apply to the epi nodes/claims (C3, C4): · VICP — preponderance of the evidence. · CICP (off-Table) — compelling, reliable, valid medical and scientific evidence (higher bar).
Bradford Hill assessment (computed)
Each viewpoint is derived from the node statuses below (see the framework crosswalk in compensation-tables-schema.md §8). Hill's viewpoints are aids to judgement, not a scoring checklist that proves causation; temporality is the only strictly necessary criterion.
Viewpoint
What it asks
Status (from evidence)
Temporality(necessary)
cause precedes effect in a plausible window (necessary)
NASEM (formerly IOM), "Adverse Effects of Vaccines: Evidence and Causality" (2011, updated 2024). Independent grading of epidemiologic and mechanistic evidence, synthesized into one of four causal-conclusion categories. This is a computed approximation of that framework, not a NASEM determination. See compensation-tables-schema.md §8bis.
Case-definition standard: Brighton Collaboration (named in spec §1: myocarditis/pericarditis) — governs the case-certainty scale on A1/A2/A6/A8 below. See compensation-tables-schema.md §8ter.
Evidence matrix (68 nodes by workstream)
68 of 68 nodes evaluated · 136 PubMed queries logged (supporting + mirror, incl. zeros). Statuses are computed from retrieved citations; not hand-set.
Definition & attribution 24/24 evaluated
A1 · Case reportssupports
Measure: New definite object in risk window T Comparator: Pre-vaccination baseline Hit rule: Definite object present, onset in window, competing causes considered
Finding: Case reports describe pericarditis, myopericarditis, or constrictive pericarditis with onset hours to 2 weeks after COVID-19 mRNA vaccination, with elevated troponin, ECG changes, and imaging findings, after considering competing causes.
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
ambiguous 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
does_not_resolve 37692656 · Cureus (2023) — Takotsubo Cardiomyopathy Following COVID-19 Vaccine Booster Dose: A Case Report.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
A2 · Series with objective confirmationsupports
Measure: Definite object plus objective test Comparator: Reference range / diagnostic criteria Hit rule: Objective confirmation in >=1 case per the working definition
Finding: Multiple case reports describe pericarditis with objective confirmation (e.g., ECG consistent with pericarditis, echocardiographic pericardial thickening/effusion, cardiac MRI findings, or pathology) in young males following mRNA COVID-19 vaccination, with onset typically within days to two weeks after the second dose.
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
does_not_resolve 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
ambiguous 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
supports_node 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
A3 · Onset histogramsupports
Measure: Distribution of onset times after dose Comparator: Pre-specified risk window Hit rule: Onset clusters inside the pre-specified window (not uniform/flat)
Finding: Multiple case reports describe pericarditis or myopericarditis onset clustering within days to two weeks after mRNA COVID-19 vaccination, with several cases reporting symptom onset within 6 hours to 2 days post-dose.
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
ambiguous 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
does_not_resolve 37692656 · Cureus (2023) — Takotsubo Cardiomyopathy Following COVID-19 Vaccine Booster Dose: A Case Report.
supports_node 35935395 · European heart journal. Case reports (2022) — Case report: mRNA COVID-19 vaccine-related acute pericarditis with evolution to myopericarditis.
A4 · Temporal plausibilitysupports
Measure: Onset latency vs object pathophysiology Comparator: Object's known natural latency Hit rule: Onset latency consistent with the object's pathophysiology
Finding: Multiple case reports describe pericarditis or myopericarditis onset within hours to 2 weeks after mRNA COVID-19 vaccination, with several cases reporting symptom onset at 6 hours, 2 days, or 2 weeks post-vaccination, consistent with a plausible temporal latency for vaccine-associated pericarditis.
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
ambiguous 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
does_not_resolve 37692656 · Cureus (2023) — Takotsubo Cardiomyopathy Following COVID-19 Vaccine Booster Dose: A Case Report.
supports_node 35935395 · European heart journal. Case reports (2022) — Case report: mRNA COVID-19 vaccine-related acute pericarditis with evolution to myopericarditis.
A5 · Onset-interval documentationsupports
Measure: Onset interval documented in source Comparator: Dose date Hit rule: Onset interval is recorded (not imputed) in a primary source
Finding: Multiple case reports document explicit onset intervals for pericarditis or myopericarditis after COVID-19 mRNA vaccination, e.g., onset 6 hours, 2 days, 7 days, or 2 weeks post-dose. Onset intervals are directly stated in the primary sources (e.g., PMID 35154981, 36301659, 38025132, 35663660, 35935395).
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
ambiguous 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
does_not_resolve 37692656 · Cureus (2023) — Takotsubo Cardiomyopathy Following COVID-19 Vaccine Booster Dose: A Case Report.
supports_node 35935395 · European heart journal. Case reports (2022) — Case report: mRNA COVID-19 vaccine-related acute pericarditis with evolution to myopericarditis.
A6 · Differential diagnosis excludedmixed
Measure: Competing causes assessed and excluded Comparator: Likely alternative diagnoses Hit rule: Pre-specified competing causes ruled out per the working definition
Finding: A single case report describes a 24-year-old male with chest pain and elevated troponin starting 6 hours after second dose of Pfizer-BioNTech COVID-19 vaccine, but the abstract does not explicitly state that competing causes (e.g., viral pericarditis, autoimmune conditions) were systematically assessed and excluded per a working definition.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
supports_node 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
supports_node 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 40902666 · Journal of the American Academy of Derma (2026) — Drug and vaccine-associated pemphigoid in patients aged 50 years and older: A pharmacovigilance study.
does_not_resolve 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 35355663 · Respirology case reports (2022) — COVID-19 mRNA vaccine-related interstitial lung disease: Two case reports and literature review.
Measure: Object recurs on a further dose Comparator: First-dose response Hit rule: Object recurs after a subsequent dose (re-exposure)
Finding: Multiple case reports describe pericarditis or myopericarditis occurring after a second dose or booster dose of an mRNA COVID-19 vaccine, indicating recurrence upon re-exposure in some patients.
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
ambiguous 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
ambiguous 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
does_not_resolve 37692656 · Cureus (2023) — Takotsubo Cardiomyopathy Following COVID-19 Vaccine Booster Dose: A Case Report.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
supports_node 35935395 · European heart journal. Case reports (2022) — Case report: mRNA COVID-19 vaccine-related acute pericarditis with evolution to myopericarditis.
A8 · Adjudicated by criteria (Brighton Collaboration)no_data
Measure: Object adjudicated by published criteria Comparator: Published clinical / Brighton criteria Hit rule: Cases adjudicated to 'definite' by a published criterion set
Finding: The retrieved evidence includes several case reports and case series describing pericarditis, myopericarditis, and perimyocarditis after COVID-19 mRNA vaccination, with onset typically within days to two weeks after the second dose or booster. However, none of the cases are explicitly described as having been adjudicated as 'definite' by a published criterion set, as required by the node's hit rule.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis case report OR case series Adjudicated by criteria pubmed · 136 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis alternative diagnosis OR not vaccine-related pubmed · 4056 hits · run 2026-09-07
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
ambiguous 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
ambiguous 37692656 · Cureus (2023) — Takotsubo Cardiomyopathy Following COVID-19 Vaccine Booster Dose: A Case Report.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
supports_node 35935395 · European heart journal. Case reports (2022) — Case report: mRNA COVID-19 vaccine-related acute pericarditis with evolution to myopericarditis.
A9 · Natural-history consistencysupports
Measure: Course matches the object's natural history Comparator: Known natural history of the object Hit rule: Clinical course (onset, peak, recovery) matches the object's natural history
Finding: The retrieved evidence includes multiple case reports of pericarditis, myopericarditis, or perimyocarditis occurring within days to weeks after COVID-19 vaccination (e.g., 6 hours, 2 days, 17 days, 2 weeks), with clinical courses showing onset, peak, and recovery consistent with the natural history of vaccine-associated pericarditis, though the evidence is limited to case reports and small case series.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36038960 · Journal of Korean medical science (2022) — A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax(®)) COVID-19 Vaccination.
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
supports_node 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
A10 · No confounding objectsupports
Measure: Not attributable to a co-occurring condition Comparator: Co-occurring illness that could produce the object Hit rule: Object not better explained by a co-occurring condition (infection, etc.)
Finding: Multiple case reports describe pericarditis or myopericarditis following COVID-19 mRNA vaccination, with onset within hours to days after dose, primarily in young males, and without evidence of concurrent infection or competing cause in the cases.
supports_node 36301659 · WMJ : official publication of the State (2022) — Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis.
does_not_resolve 37214139 · Clinical and experimental vaccine resear (2023) — A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis.
supports_node 35371688 · Cureus (2022) — Myocarditis Secondary to COVID-19 mRNA Vaccine: A Case Report.
supports_node 36540512 · Cureus (2022) — COVID-19 Vaccine-Induced Acute Perimyocarditis: A Case Report.
does_not_resolve 37692656 · Cureus (2023) — Takotsubo Cardiomyopathy Following COVID-19 Vaccine Booster Dose: A Case Report.
supports_node 38025132 · European heart journal. Case reports (2023) — A case report of constrictive pericarditis following COVID-19 vaccination.
supports_node 35935395 · European heart journal. Case reports (2022) — Case report: mRNA COVID-19 vaccine-related acute pericarditis with evolution to myopericarditis.
D1 · Predicted site of injuryno_data
Measure: Object at the site the mechanism predicts Comparator: Predicted anatomic site from the mechanism Hit rule: Object localizes to the anatomic site the mechanism predicts
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis anatomic localization Predicted site of injury mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Predicted site of injury not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D2 · Spared structuresno_data
Measure: Structures the mechanism should spare are spared Comparator: Structures predicted unaffected Hit rule: Structures predicted spared by the mechanism are indeed spared
mirror: COVID-19 vaccine Pericarditis Spared structures not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D3 · Local vs systemic distributionno_data
Measure: Distribution matches mechanism scope Comparator: Local (injection site) vs systemic expectation Hit rule: Observed distribution (local vs systemic) matches the mechanism's predicted scope
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis anatomic localization Local vs systemic distribution mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Local vs systemic distribution not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D4 · Kinetics classno_data
Measure: Onset/offset kinetics match the mechanism Comparator: Expected kinetic class (acute vs chronic) Hit rule: Onset and offset kinetics are in the class the mechanism predicts
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis anatomic localization Kinetics class mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Kinetics class not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
D5 · Platform-mechanism matchno_data
Measure: Mechanism is consistent with the platform Comparator: Mechanistic expectation for the platform Hit rule: The proposed mechanism is biologically consistent with the vaccine platform
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis anatomic localization Platform-mechanism match mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Platform-mechanism match not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
H3 · Targeted treatment reversesno_data
Measure: A targeted treatment reverses the object in patients Comparator: Treatment-naive / placebo Hit rule: A mechanism-directed treatment reverses the object (vs control treatment)
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Targeted treatment reverses intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
Measure: No node's finding contradicts another Comparator: Internal consistency across nodes Hit rule: No evaluated node directly contradicts another (coherence)
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis No internal contradiction coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis No internal contradiction inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
I2 · Analogy to a known objectno_data
Measure: Object analogous to a well-established analog Comparator: Established analog's profile Hit rule: The object's profile matches a well-established analog on key features
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Analogy to a known object coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Analogy to a known object inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
I5 · Latency coherenceno_data
Measure: Observed latency matches the mechanism's latency Comparator: Mechanism-predicted latency Hit rule: Observed onset latency is coherent with the mechanism's predicted latency
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Latency coherence coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Latency coherence inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
J1 · Pre-specificationno_data
Measure: Window/hit-rule pre-specified before data Comparator: Pre-specified vs post-hoc Hit rule: The risk window, object, and hit rule were pre-specified before data were seen
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Pre-specification pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Pre-specification post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
2 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
does_not_resolve 42569385 · Frontiers in medicine (2026) — Antibiotic-associated adverse events in bone and joint infections: a FAERS pharmacovigilance study.
J2 · Contrary-evidence logno_data
Measure: Contrary evidence is logged, not omitted Comparator: Support-only dossier Hit rule: Contrary / null / refuting findings are logged and shown alongside support
Finding: No evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Contrary-evidence log pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Contrary-evidence log post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
2 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
does_not_resolve 42474879 · Biological trace element research (2026) — Cadmium Exposure and Osteoporosis: A Spatially Contextualized Adverse Outcome Pathway Integrating Epidemiology, Toxicogenomics and Transcriptomics.
J3 · No temporality-only claimno_data
Measure: Claim not based on temporality alone Comparator: Sequence-only evidence Hit rule: The claim is not supported by temporal sequence alone (independent evidence exists)
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis No temporality-only claim pre-specified OR adjudicated pubmed · 13549 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis No temporality-only claim post-hoc OR hypothesis-generating only pubmed · 1699 hits · run 2026-09-07
3 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
does_not_resolve 42569385 · Frontiers in medicine (2026) — Antibiotic-associated adverse events in bone and joint infections: a FAERS pharmacovigilance study.
does_not_resolve 38983297 · Radiology case reports (2024) — Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report.
J4 · Passive-surveillance roleno_data
Measure: Passive-surveillance findings bounded correctly Comparator: Active-surveillance confirmation Hit rule: Passive-surveillance signals are framed as hypothesis-generating, not confirmatory
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Passive-surveillance role pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Passive-surveillance role post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
2 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
does_not_resolve 38983297 · Radiology case reports (2024) — Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report.
J5 · Dose mappingno_data
Measure: Dose/lot exposure mapped to the object Comparator: Unmapped exposure Hit rule: Dose / lot exposure is mapped to the object where the mechanism predicts it
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Dose mapping pre-specified OR adjudicated pubmed · 13548 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Dose mapping post-hoc OR hypothesis-generating only pubmed · 1698 hits · run 2026-09-07
4 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
does_not_resolve 42569385 · Frontiers in medicine (2026) — Antibiotic-associated adverse events in bone and joint infections: a FAERS pharmacovigilance study.
does_not_resolve 38983297 · Radiology case reports (2024) — Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report.
Epidemiologic chassis 13/13 evaluated
B1 · Excess vs baselinesupports
Measure: RR/IRR vs unexposed or prior window Comparator: Unvaccinated person-time or pre-vaccination window Hit rule: RR/IRR > 1 with CI excluding 1 after pre-specified confounders
Finding: PMID 34907393 reports a self-controlled case series finding increased risk of pericarditis hospital admission or death in the 1–28 days following COVID-19 vaccination (ChAdOx1, BNT162b2, mRNA-1273). PMID 40573879 and PMID 37167363 narratively describe pericarditis as a rare complication of COVID-19 mRNA vaccines.
supporting: COVID-19 vaccine Pericarditis Excess vs baseline incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Excess vs baseline pubmed · 88701 hits · run 2026-09-07
17 retrieved record(s)
refutes_node 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 33773635 · The Lancet. Public health (2021) — Periods of altered risk for non-fatal drug overdose: a self-controlled case series.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 40818314 · Vaccine (2025) — COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 36226469 · Epilepsia (2022) — Association between the risk of seizure and COVID-19 vaccinations: A self-controlled case-series study.
does_not_resolve 35489031 · Journal of clinical psychopharmacology (2022) — Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational Studies.
B2 · SCCSno_data
Measure: Self-controlled case series risk ratio Comparator: Individuals' own risk intervals (no-event) Hit rule: SCCS risk ratio > 1 in the post-vaccination window, CI excluding 1
Finding: No study in the retrieved evidence directly reports a self-controlled case series risk ratio for pericarditis specifically following COVID-19 vaccination, with a confidence interval excluding 1.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis SCCS incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk SCCS pubmed · 88807 hits · run 2026-09-07
18 retrieved record(s)
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 33773635 · The Lancet. Public health (2021) — Periods of altered risk for non-fatal drug overdose: a self-controlled case series.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 40818314 · Vaccine (2025) — COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
does_not_resolve 36226469 · Epilepsia (2022) — Association between the risk of seizure and COVID-19 vaccinations: A self-controlled case-series study.
does_not_resolve 35489031 · Journal of clinical psychopharmacology (2022) — Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational Studies.
B3 · Cohort / risk-intervalsupports
Measure: Incidence rate ratio in defined window Comparator: Pre-specified risk vs comparison interval Hit rule: IRR > 1 in the pre-specified window, CI excluding 1, stratified by age/sex
Finding: The retrieved evidence includes a self-controlled case series (SCCS) study (PMID 34907393) that specifically reports an increased risk of pericarditis following COVID-19 vaccination (IRR > 1, CI excluding 1) in a pre-specified risk window, with stratification by age/sex, meeting the hit rule for node B3. Other retrieved studies (e.g., PMID 37167363, 40573879) mention pericarditis as a rare adverse event but do not provide SCCS-derived incidence rate ratios with CIs for this specific node.
supporting: COVID-19 vaccine Pericarditis Cohort / risk-interval incidence risk cohort OR self-controlled case series pubmed · 946 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Cohort / risk-interval pubmed · 88309 hits · run 2026-09-07
17 retrieved record(s)
does_not_resolve 30172612 · American journal of infection control (2019) — Antibiotic exposure and risk of community-associated Clostridium difficile infection: A self-controlled case series analysis.
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 33773635 · The Lancet. Public health (2021) — Periods of altered risk for non-fatal drug overdose: a self-controlled case series.
does_not_resolve 40818314 · Vaccine (2025) — COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
ambiguous 37167363 · Circulation research (2023) — COVID-19, Myocarditis and Pericarditis.
B4 · Meta-analysis / poolingno_data
Measure: Pooled effect across studies Comparator: Pooled estimate with heterogeneity Hit rule: Pooled estimate > 1 (or < 1) with quantified heterogeneity (I2)
Finding: No pooled meta-analysis or quantitative synthesis of effect estimates with heterogeneity was retrieved; the available studies use self-controlled case series designs or are reviews without meta-analysis of the COVID-19 vaccine–pericarditis association.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Meta-analysis / pooling incidence risk cohort OR self-controlled case series pubmed · 946 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Meta-analysis / pooling pubmed · 112139 hits · run 2026-09-07
15 retrieved record(s)
refutes_node 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 33773635 · The Lancet. Public health (2021) — Periods of altered risk for non-fatal drug overdose: a self-controlled case series.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 40818314 · Vaccine (2025) — COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
ambiguous 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
refutes_node 36226469 · Epilepsia (2022) — Association between the risk of seizure and COVID-19 vaccinations: A self-controlled case-series study.
does_not_resolve 35489031 · Journal of clinical psychopharmacology (2022) — Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational Studies.
B5 · Negative-control outcomesno_data
Measure: No excess for outcomes the vaccine should not cause Comparator: Negative-control outcomes (unaffected by mechanism) Hit rule: Null for negative-control outcomes while target outcome is positive (specificity)
Finding: The retrieved evidence does not include a study specifically evaluating negative-control outcomes for COVID-19 vaccine and pericarditis; the available studies primarily focus on risk of pericarditis as a target outcome or on other endpoints such as arrhythmias, Guillain-Barré syndrome, or rotavirus vaccine safety, with no reported null findings for pericarditis as a negative-control outcome.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Negative-control outcomes incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Negative-control outcomes pubmed · 88512 hits · run 2026-09-07
11 retrieved record(s)
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
ambiguous 37167363 · Circulation research (2023) — COVID-19, Myocarditis and Pericarditis.
ambiguous 40573879 · Vaccines (2025) — Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.
ambiguous 36161056 · World journal of cardiology (2022) — COVID-19 vaccine-associated myocarditis.
refutes_node 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
B6 · Other-antigen comparisonno_data
Measure: Risk vs a different-antigen comparator Comparator: Comparator product with a different antigen Hit rule: Risk specific to the target antigen, not shared with the comparator antigen
Finding: No retrieved study directly compares the risk of pericarditis after COVID-19 vaccination versus a different-antigen comparator; the closest evidence is from a self-controlled case series (PMID 34907393) that estimated risks after COVID-19 vaccines versus SARS-CoV-2 infection, not versus another vaccine antigen. Other retrieved studies are reviews or case reports without a different-antigen comparator.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Other-antigen comparison incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Other-antigen comparison pubmed · 88274 hits · run 2026-09-07
15 retrieved record(s)
does_not_resolve 30172612 · American journal of infection control (2019) — Antibiotic exposure and risk of community-associated Clostridium difficile infection: A self-controlled case series analysis.
refutes_node 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
ambiguous 37167363 · Circulation research (2023) — COVID-19, Myocarditis and Pericarditis.
ambiguous 40573879 · Vaccines (2025) — Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.
ambiguous 36161056 · World journal of cardiology (2022) — COVID-19 vaccine-associated myocarditis.
B7 · Absolute riskno_data
Measure: Per-100k risk in window Comparator: Absolute incidence per 100k Hit rule: Absolute risk reported and stable across the window (not an artifact of rarity)
Finding: No retrieved evidence provides a per-100k absolute risk estimate for pericarditis following COVID-19 vaccination that is stable and not an artifact of rarity.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Absolute risk incidence risk cohort OR self-controlled case series pubmed · 950 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Absolute risk pubmed · 111535 hits · run 2026-09-07
15 retrieved record(s)
does_not_resolve 30172612 · American journal of infection control (2019) — Antibiotic exposure and risk of community-associated Clostridium difficile infection: A self-controlled case series analysis.
does_not_resolve 33773635 · The Lancet. Public health (2021) — Periods of altered risk for non-fatal drug overdose: a self-controlled case series.
does_not_resolve 40818314 · Vaccine (2025) — COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 37167363 · Circulation research (2023) — COVID-19, Myocarditis and Pericarditis.
does_not_resolve 29211679 · The New England journal of medicine (2017) — Contemporary Hormonal Contraception and the Risk of Breast Cancer.
B8 · Platform splitsupports
Measure: Risk by vaccine platform / product Comparator: Platform (mRNA vs viral vector, etc.) Hit rule: Risk attributable to a specific platform, not to 'a vaccine' generally
Finding: The retrieved evidence includes a large self-controlled case series (PMID 34907393) that specifically estimated risks of pericarditis separately for adenovirus (ChAdOx1) and mRNA-based (BNT162b2, mRNA-1273) COVID-19 vaccines, thereby providing platform-specific risk estimates. Additional reviews (PMID 40573879, PMID 36161056) confirm that pericarditis is associated with mRNA vaccines specifically (e.g., a rare complication of COVID-19 mRNA vaccination).
supporting: COVID-19 vaccine Pericarditis Platform split incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Platform split pubmed · 88339 hits · run 2026-09-07
13 retrieved record(s)
does_not_resolve 30172612 · American journal of infection control (2019) — Antibiotic exposure and risk of community-associated Clostridium difficile infection: A self-controlled case series analysis.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
ambiguous 37167363 · Circulation research (2023) — COVID-19, Myocarditis and Pericarditis.
does_not_resolve 40573879 · Vaccines (2025) — Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.
ambiguous 36161056 · World journal of cardiology (2022) — COVID-19 vaccine-associated myocarditis.
refutes_node 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
B9 · Host-structure stratificationsupports
Measure: Risk by age / sex / host structure Comparator: Unstratified estimate Hit rule: Risk concentrated in a defined host subgroup (e.g. young males), stable across sources
Finding: Evidence from self-controlled case series studies indicates that the risk of pericarditis is elevated in young males after COVID-19 mRNA vaccination, particularly following the second dose, with the highest risk concentrated in this subgroup and the association stable across multiple sources.
supporting: COVID-19 vaccine Pericarditis Host-structure stratification incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Host-structure stratification pubmed · 88272 hits · run 2026-09-07
18 retrieved record(s)
does_not_resolve 30172612 · American journal of infection control (2019) — Antibiotic exposure and risk of community-associated Clostridium difficile infection: A self-controlled case series analysis.
ambiguous 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 33773635 · The Lancet. Public health (2021) — Periods of altered risk for non-fatal drug overdose: a self-controlled case series.
does_not_resolve 40818314 · Vaccine (2025) — COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 37223097 · Frontiers in immunology (2023) — Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
ambiguous 37167363 · Circulation research (2023) — COVID-19, Myocarditis and Pericarditis.
B10 · Formulation / component changeno_data
Measure: Risk tracks a formulation change Comparator: Pre- vs post-change formulation Hit rule: Risk change tracks a documented formulation / component change over time
Finding: The retrieved evidence does not contain any study that tracks pericarditis risk following COVID-19 vaccination in relation to a documented formulation or component change over time.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Formulation / component change incidence risk cohort OR self-controlled case series pubmed · 945 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no association OR null OR no increased risk Formulation / component change pubmed · 88434 hits · run 2026-09-07
11 retrieved record(s)
does_not_resolve 38089855 · European heart journal open (2023) — Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
does_not_resolve 40440921 · Vaccine (2025) — Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
ambiguous 37167363 · Circulation research (2023) — COVID-19, Myocarditis and Pericarditis.
ambiguous 40573879 · Vaccines (2025) — Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.
ambiguous 36161056 · World journal of cardiology (2022) — COVID-19 vaccine-associated myocarditis.
refutes_node 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
H2 · Formulation natural experimentno_data
Measure: Risk shifts with a formulation change in the field Comparator: Pre- vs post-change formulation Hit rule: Observed risk tracks a real-world formulation change (natural experiment)
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Formulation natural experiment intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
Measure: Risk signal appears/disappears across a pause or policy change Comparator: Pre- vs post-pause period Hit rule: The signal appears or disappears coherently with a rollout / pause (H4)
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Policy / pause signal intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Policy / pause signal no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-07
I3 · Infection coherenceno_data
Measure: Pattern is coherent with or distinct from infection Comparator: Infection-matched comparison Hit rule: The post-vaccine pattern is coherent with (or clearly distinct from) the infection pattern
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Infection coherence coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Infection coherence inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
1 retrieved record(s)
does_not_resolve 25187623 · Reproduction (Cambridge, England) (2014) — Epigenetics and life-long consequences of an adverse nutritional and diabetic intrauterine environment.
Mediator & biological gradient 24/24 evaluated
C1n · Dose strength gradientno_data
Measure: Risk vs dose strength (dose size) Comparator: Lower dose strength Hit rule: Monotonic dose-response in dose strength (larger dose -> higher risk)
Finding: No retrieved study directly compares risk by dose strength (e.g., full dose vs. half dose, different mRNA platforms with differing antigen content) for pericarditis after COVID-19 vaccination.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Dose strength gradient dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no dose effect OR no dose-response Dose strength gradient pubmed · 275 hits · run 2026-09-07
10 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
supports_node 38350768 · Vaccine (2024) — COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
supports_node 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
ambiguous 36988252 · Immunity, inflammation and disease (2023) — Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
supports_node 34907393 · Nature medicine (2022) — Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
ambiguous 37868673 · Journal of community hospital internal m (2023) — Covid- 19 Vaccine-induced Myocarditis.
C2n · Dose number gradientsupports
Measure: Risk vs dose number (1st vs 2nd vs 3rd) Comparator: First dose Hit rule: Risk increases (or shows a defined pattern) with dose number
Finding: Several studies report that myocarditis/pericarditis risk is higher after the second dose of mRNA COVID-19 vaccines, particularly in young males, and that rates are elevated within a week of receiving the second dose; this suggests a dose-number gradient with higher risk following dose 2 versus dose 1. However, evidence on risk after third (booster) doses compared to earlier doses is not explicitly addressed in the retrieved abstracts.
supporting: COVID-19 vaccine Pericarditis Dose number gradient dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no dose effect OR no dose-response Dose number gradient pubmed · 719 hits · run 2026-09-07
13 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
does_not_resolve 34776011 · Infectious diseases of poverty (2021) — Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
supports_node 38350768 · Vaccine (2024) — COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
refutes_node 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
does_not_resolve 36988252 · Immunity, inflammation and disease (2023) — Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
supports_node 34907393 · Nature medicine (2022) — Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
C3n · Measured-exposure tertilesno_data
Measure: Risk vs measured exposure tertile Comparator: Lowest-exposure tertile Hit rule: Risk ordered by measured-exposure tertile (high > mid > low)
Finding: The retrieved evidence includes multiple studies and reviews indicating an elevated risk of pericarditis (often grouped with myocarditis) following COVID-19 mRNA vaccination, particularly in young males after the second dose, with incidence rates such as ~12.6 cases per million doses reported in one study. However, no study in the retrieved set directly stratifies this risk by measured-exposure tertiles (e.g., antibody levels or vaccine dose concentration).
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Measured-exposure tertiles dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no dose effect OR no dose-response Measured-exposure tertiles pubmed · 164 hits · run 2026-09-07
12 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
supports_node 38350768 · Vaccine (2024) — COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
does_not_resolve 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
ambiguous 36988252 · Immunity, inflammation and disease (2023) — Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
supports_node 34907393 · Nature medicine (2022) — Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
does_not_resolve 37868673 · Journal of community hospital internal m (2023) — Covid- 19 Vaccine-induced Myocarditis.
C4n · Organoid concentration curveno_data
Measure: Effect vs antigen concentration in organoid Comparator: Vehicle / zero antigen Hit rule: Dose-dependent effect across a graded concentration curve
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Organoid concentration curve dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no dose effect OR no dose-response Organoid concentration curve pubmed · 175 hits · run 2026-09-07
12 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 36090988 · Frontiers in immunology (2022) — A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
supports_node 38350768 · Vaccine (2024) — COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
refutes_node 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
ambiguous 36988252 · Immunity, inflammation and disease (2023) — Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
supports_node 34907393 · Nature medicine (2022) — Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
does_not_resolve 37868673 · Journal of community hospital internal m (2023) — Covid- 19 Vaccine-induced Myocarditis.
C5n · EC50 vs Cmax coherencesupports
Measure: Measured exposure reaches effect threshold Comparator: Pharmacokinetic Cmax vs EC50 Hit rule: Achieved exposure (Cmax/tissue) plausibly reaches the in-vitro EC50
Finding: Multiple epidemiological studies and reviews report that pericarditis/myopericarditis is a rare adverse event following COVID-19 mRNA vaccination, with higher rates in young males within days of the second dose, and that the incidence is lower than that following SARS-CoV-2 infection.
supporting: COVID-19 vaccine Pericarditis EC50 vs Cmax coherence dose-response OR dose effect pubmed · 1299132 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis no dose effect OR no dose-response EC50 vs Cmax coherence pubmed · 164 hits · run 2026-09-07
11 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
supports_node 38350768 · Vaccine (2024) — COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
refutes_node 34477808 · JAMA (2021) — Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
supports_node 36988252 · Immunity, inflammation and disease (2023) — Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
supports_node 34907393 · Nature medicine (2022) — Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
ambiguous 37868673 · Journal of community hospital internal m (2023) — Covid- 19 Vaccine-induced Myocarditis.
supports_node 35289493 · Internal medicine journal (2023) — COVID-19 mRNA vaccines and myopericarditis.
E1 · Mediator identified in casesno_data
Measure: Mediator present in affected tissue/cells Comparator: Unaffected tissue / control Hit rule: The hypothesized mediator is detected in the affected compartment and not (or less) in control
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Mediator identified in cases in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Mediator identified in cases not associated mechanism pubmed · 2 hits · run 2026-09-07
1 retrieved record(s)
refutes_node 37716365 · The Lancet. Respiratory medicine (2023) — Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-bl
E2 · Mediator in healthy vaccineesno_data
Measure: Mediator detectable after vaccination Comparator: Pre-vaccination baseline Hit rule: Mediator appears after vaccination and tracks the exposure window
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Mediator in healthy vaccinees in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Mediator in healthy vaccinees not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E3 · Infection contrastmixed
Measure: Mediator absent/low after natural infection Comparator: Recovered natural infection Hit rule: Mediator signal is specific to vaccination vs a comparable natural-infection control
Finding: The retrieved evidence indicates that pericarditis/myocarditis rates are higher after COVID-19 infection than after COVID-19 vaccination (PMID 36441403), and that COVID-19 vaccine-related cases are typically transient and self-limited. However, no study in the retrieved set directly compares pericarditis-specific mediator signals after vaccination versus natural infection, nor provides quantitative data on mediator absence or low levels following natural infection.
supporting: COVID-19 vaccine Pericarditis mechanism Infection contrast in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Infection contrast not associated mechanism pubmed · 8 hits · run 2026-09-07
5 retrieved record(s)
supports_node 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 39225797 · Archives of toxicology (2024) — A review of the scientific literature on experimental toxicity studies of COVID-19 vaccines, with special attention to publications in toxicology journals.
supports_node 35230520 · European radiology (2022) — Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: a multicenter collection of 27 cases.
supports_node 36576105 · Infectious diseases (London, England) (2023) — Admission and follow-up cardiac magnetic resonance imaging findings in BNT162b2 Vaccine-Related myocarditis in adolescents.
supports_node 37828636 · British journal of pharmacology (2024) — Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure.
E4 · Transfer to recipientno_data
Measure: Phenotype/mediator transferred to a recipient system Comparator: Control transfer Hit rule: The effect / mediator transfers to a naive recipient system
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Transfer to recipient in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Transfer to recipient not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E5 · Transfer specificityno_data
Measure: Transfer requires the specific mediator Comparator: Transfer with mediator present Hit rule: Transfer effect is lost when the specific mediator is removed
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Transfer specificity in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Transfer specificity not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E6 · Depletion / knockdownno_data
Measure: Removing the mediator reduces the effect Comparator: Non-targeted knockdown Hit rule: Knockdown / depletion of the mediator reduces the phenotype
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Depletion / knockdown in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
Measure: Adding the mediator restores the effect Comparator: Add-back of a control protein Hit rule: Adding back the mediator (not a control) restores the phenotype
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Add-back rescue in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Add-back rescue not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
E8 · Neutralizationno_data
Measure: Neutralizing the mediator blocks the effect Comparator: Isotype control Hit rule: Neutralization of the mediator (not an isotype control) blocks the phenotype
Finding: No evidence was found that directly tests whether neutralization of a mediator blocks the phenotype of pericarditis after COVID-19 vaccination. Retrieved studies focus on immunogenicity, safety profiles, and adverse event reporting but do not include neutralization experiments targeting mediators of pericarditis.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Neutralization in vitro OR patient-derived pubmed · 29240 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Neutralization not associated mechanism pubmed · 11 hits · run 2026-09-07
9 retrieved record(s)
ambiguous 38141632 · The Lancet. Infectious diseases (2024) — Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicen
ambiguous 35544369 · The New England journal of medicine (2022) — Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
does_not_resolve 38615382 · International immunopharmacology (2024) — Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study.
refutes_node 40195167 · Expert review of vaccines (2025) — Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study.
refutes_node 42647564 · Human vaccines & immunotherapeutics (2026) — Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.
does_not_resolve 42506605 · Vaccines (2026) — Rationally Modified SARS-CoV-2 Spike Protein Impairs ACE2 Binding While Preserving Immunogenicity in Mice.
does_not_resolve 39874991 · The Journal of infection (2025) — Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.
does_not_resolve 41722533 · Vaccine (2026) — Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.
E9 · Isotype controlno_data
Measure: Isotype control does not reproduce the effect Comparator: Active antibody Hit rule: An isotype control fails to reproduce the block/activation
Finding: The abstract reports on the safety of the BNT162b2 mRNA COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases and the general population but does not mention isotype control experiments or their failure to reproduce block/activation related to pericarditis.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Isotype control in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Isotype control not associated mechanism pubmed · 2 hits · run 2026-09-07
1 retrieved record(s)
supports_node 34127481 · Annals of the rheumatic diseases (2021) — Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population:
F1 · Full product reproducesno_data
Measure: Full vaccine product reproduces the effect Comparator: No-product control Hit rule: The full product (not a subcomponent) reproduces the effect
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Full product reproduces component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Full product reproduces no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F2 · Empty vector / particleno_data
Measure: Vector/particle without antigen reproduces (or not) Comparator: Full product Hit rule: Effect attributed to (or excluded from) the vector/particle backbone alone
Finding: The retrieved evidence discusses viral and bacterial vaccine vectors in general (influenza, measles, adenovirus, Newcastle disease virus, and live bacterial vectors) but does not contain any data on COVID-19 vaccines, pericarditis, or the effect of an empty vector/particle backbone alone on pericarditis.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Empty vector / particle component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F3 · Antigen alone reproducesno_data
Measure: Isolated antigen reproduces the effect Comparator: Vehicle Hit rule: The isolated antigen (not the full product) reproduces the effect
Finding: The retrieved evidence discusses live bacterial and viral vaccine vectors used to deliver heterologous antigens, but none of the abstracts describe experiments where the isolated antigen component of a COVID-19 vaccine was administered alone to test whether it reproduces pericarditis.
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Antigen alone reproduces component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F4 · Irrelevant cargono_data
Measure: Irrelevant cargo does not reproduce the effect Comparator: Vector with the target antigen Hit rule: Irrelevant cargo fails to reproduce the effect (specificity)
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Irrelevant cargo component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F5 · Infection preparationno_data
Measure: Infection preparation vs product comparison Comparator: Product-derived preparation Hit rule: Effect compares correctly between infection and product preparations
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Infection preparation component OR antigen OR vector pubmed · 2045216 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F6 · Cytokine / adjuvant mixno_data
Measure: Cytokine/adjuvant mix alone reproduces (or not) Comparator: Individual components Hit rule: The effect is (or is not) reproducible by the cytokine/adjuvant mix alone
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Cytokine / adjuvant mix component OR antigen OR vector pubmed · 2045214 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F7 · Component combinationno_data
Measure: Defined component combination reproduces the effect Comparator: Single components Hit rule: A defined combination reproduces the effect that single components do not
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Component combination component OR antigen OR vector pubmed · 2045216 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Component combination no effect component isolation pubmed · 1 hits · run 2026-09-07
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
ambiguous 34833382 · Medicina (Kaunas, Lithuania) (2021) — Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis.
G1 · 2D human cellsno_data
Measure: Effect reproduced in 2D human cell culture Comparator: Untreated / control cells Hit rule: Effect reproduced in 2D primary human cells
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis 2D human cells animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis 2D human cells not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G2 · Organoid / chipno_data
Measure: Effect reproduced in organoid / organ-on-chip Comparator: Unexposed organoid Hit rule: Effect reproduced in a 3D organoid / organ-on-chip system
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Organoid / chip animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Organoid / chip not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
H1 · Block in vitro / in vivono_data
Measure: Blocking the mediator/mechanism prevents the effect Comparator: Control intervention Hit rule: Blocking the mechanism prevents or reverses the effect (not with a control intervention)
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Block in vitro / in vivo intervention OR treatment OR reversal pubmed · 15141378 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Block in vitro / in vivo no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-07
Clinical / animal / host 7/7 evaluated
E10 · Host-line dependenceno_data
Measure: Effect depends on host line/cell type Comparator: Susceptible host line Hit rule: Effect is restricted to a defined host line / genotype, not universal
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis mechanism Host-line dependence in vitro OR patient-derived pubmed · 29239 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Host-line dependence not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G3 · Animal, clinical routeno_data
Measure: Effect in animal via the clinical route of administration Comparator: Vehicle, same route Hit rule: Effect reproduced in an animal using the clinical route of administration
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Animal, clinical route animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Animal, clinical route not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G4 · Susceptible animalno_data
Measure: Effect in a susceptible animal model Comparator: Non-susceptible model Hit rule: Effect in a defined susceptible animal model
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Susceptible animal animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Susceptible animal not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G5 · Replication across labsno_data
Measure: Effect replicated in an independent lab Comparator: Original result Hit rule: The key effect is replicated in an independent laboratory
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Replication across labs animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Replication across labs not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G6 · Blinded scoringno_data
Measure: Outcomes scored blinded Comparator: Unblinded reference Hit rule: Primary outcomes scored by a blinded assessor
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Blinded scoring animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Blinded scoring not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-07
G7 · Experimental time coursesupports
Measure: Effect follows a defined experimental time course Comparator: No-exposure time course Hit rule: The effect's onset/offset follows a defined experimental time course
Finding: In a cohort of 44 patients with vaccine-associated myocarditis, pericarditis, or myopericarditis following COVID-19 vaccination, the case definition required symptom onset within 25 days of the last vaccine dose, which aligns with a defined experimental time course for this node.
supporting: COVID-19 vaccine Pericarditis Experimental time course animal OR organoid OR cell model pubmed · 1818474 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Experimental time course not reproduced model pubmed · 1 hits · run 2026-09-07
1 retrieved record(s)
supports_node 36913155 · The international journal of cardiovascu (2023) — Short term outcome of myocarditis and pericarditis following COVID-19 vaccines: a cardiac magnetic resonance imaging study.
I4 · Susceptibility traitno_data
Measure: A host trait / marker defines susceptibility Comparator: Trait-negative hosts Hit rule: A defined host trait / marker enriches for susceptibility
Finding: no evidence found
Cited: (none)
supporting: COVID-19 vaccine Pericarditis Susceptibility trait coherence OR latency OR susceptibility pubmed · 870020 hits · run 2026-09-07
mirror: COVID-19 vaccine Pericarditis Susceptibility trait inconsistent OR contradicts pubmed · 27612 hits · run 2026-09-07
How this was built
Per node: a supporting and a mirror PubMed query built from the node's measure / population / comparator / hit_rule; top hits fetched (title + abstract); each record classified (supports / refutes / ambiguous) by xAI with a heuristic fallback; a per-node synthesis is generated strictly from the retrieved PMIDs; the node status is then rolled up to C1–C6. Full query provenance is shown per node above. Reproduce the build: python -m evidence_run. Data: data/evidence_run/state.json.